STAT

STAT+: Pharmalittle: We’re reading about the Cencora data breach, a failed pandemic treaty, and more

Good morning, everyone, and welcome to another working week. We hope the weekend respite — which was extended on this side of the pond thanks to a holiday — was relaxing and invigorating. Now, though, the time has come to resume the usual routines of online meetings, phone calls, and what-not.

After all, the world continues to spin, although it remains a bit wobbly where we are after losing a Pharmalot ancestor, which explains our recent disappearance. To cope, we are brewing a cup of stimulation. Our choice today is hot buttery rum. As always, you are invited to join us. We hope your day is productive and meaningful. Either way, do keep in touch. …

Almost a dozen pharmaceutical companies have lost sensitive customer data due to a supply chain cyberattack that trickled down from Cencora, TechRadar writes. In late February, the wholesaler — previously known as AmerisourceBergen — disclosed a data breach incident with few details. But 11 drug companies have now submitted almost identical breach notification letters to the California Attorney General’s office claiming a data breach as a result of the Cencora incident. Among them is Novartis, GSK, Bayer, AbbVie, Regeneron Pharmaceuticals, Genentech, Incyte, Sumitomo Pharma America, and Acadia Pharmaceuticals.

A last-ditch effort by World Health Organization member states failed to finish negotiations on a pandemic accord ahead of the World Health Assembly meeting this week, The New York Times reports. The key articles in the draft text that remained unresolved included the thorny formula for global sharing of vaccines and medicines during international health emergencies. Among the most contentious issues in the draft treaty is a section called Pathogen Access and Benefits Sharing, under which countries would be required to swiftly share genetic sequences and samples of emerging pathogens. These data are crucial for rapid development of diagnostic tests, vaccines, and treatments.

Continue to STAT+ to read the full story…

10 months 3 weeks ago

Pharma, Pharmalot, pharmalittle, STAT+

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

AbbVie concludes acquisition of Landos Biopharma

North Chicago, Ill.: AbbVie has announced that it has completed its acquisition of Landos Biopharma, Inc. With the completion of the acquisition, Landos is now part of AbbVie.

Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family), which is currently in Phase 2 for the treatment of moderate to severe UC (NEXUS study; NCT05785715). NLRX1 regulates immunometabolism and inflammation, and its activation may address inflammatory bowel disease (IBD) pathogenesis. With a dual mechanism of action that is anti-inflammatory and facilitates epithelial repair, NX-13 has the potential to offer a novel approach to the treatment of UC and CD.

"Many people living with IBD are not able to achieve or maintain remission and continue to experience debilitating symptoms," said Kori Wallace, M.D., Ph.D., vice president, global head of immunology clinical development, AbbVie. "The addition of NX-13 complements our portfolio in immunology and strengthens our collective efforts to transform standard of care. I want to commend the Landos team for their efforts in advancing our shared mission of developing medicines for those who need it most."

AbbVie has acquired Landos at a price of $20.42 per share, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, subject to the achievement of a clinical development milestone. Landos' common stock will cease to trade on the NASDAQ stock exchange prior to market open on May 24, 2024.

NEXUS is a Phase 2 proof-of-concept clinical trial evaluating NX-13 in patients with moderate to severe UC. NEXUS is a randomized, multicenter, double-blind, placebo-controlled, multiple dose, 12-week induction study evaluating 80 patients with moderate to severe UC with a long-term extension (LTE) period. All subjects will be randomized to receive either 250 mg or 750 mg immediate release NX-13, or placebo. The primary objective of the trial will be to evaluate clinical efficacy, safety and pharmacokinetics of oral NX-13 versus placebo (NCT05785715 ClinicalTrials.gov).

Read also: USFDA grants full approval for Abbvie Elahere for certain ovarian cancer patients

10 months 3 weeks ago

News,Industry,Pharma News,Latest Industry News

Health | NOW Grenada

PAHO evaluating Grenada’s National Immunisation Programme

“Discussions also highlighted the importance of ensuring every child is immunised against measles, rubella, polio, and pertussis to maintain the nation’s health”

10 months 3 weeks ago

Health, PRESS RELEASE, beryl irons, chisa cumberbatch, immunisation, karen broome, paho, pan american health organisation

PAHO/WHO | Pan American Health Organization

PAHO and Unitaid strengthen partnership to eliminate communicable diseases from the Americas

PAHO and Unitaid strengthen partnership to eliminate communicable diseases from the Americas

Cristina Mitchell

27 May 2024

PAHO and Unitaid strengthen partnership to eliminate communicable diseases from the Americas

Cristina Mitchell

27 May 2024

10 months 3 weeks ago

KFF Health News

La vacuna contra el sarampión es segura y eficaz. No te dejes engañar por los escépticos

Los casos de sarampión están aumentando en Estados Unidos. En el primer trimestre de este año, se registró un número de casos 17 veces mayor con respecto al promedio registrado durante el mismo período en los cuatro años anteriores, según los Centros para el Control y Prevención de Enfermedades (CDC).

Los casos de sarampión están aumentando en Estados Unidos. En el primer trimestre de este año, se registró un número de casos 17 veces mayor con respecto al promedio registrado durante el mismo período en los cuatro años anteriores, según los Centros para el Control y Prevención de Enfermedades (CDC). La mitad de las personas infectadas, principalmente niños, han sido hospitalizadas.

Y se espera que las cifras sigan empeorando, en gran medida porque cada vez más padres deciden no vacunar a sus hijos contra el sarampión y otras enfermedades como la polio y la tos ferina.

Este año, el 80% de los casos ha sido en personas no vacunadas o con un estatus de vacunación desconocido. Muchos padres han sido influenciados por una avalancha de desinformación difundida por políticos y personalidades en redes sociales, podcasts, y en la TV, que repiten falsas creencias, erosionando la confianza en la ciencia que respalda las vacunas infantiles de rutina.

A continuación, examinamos algunos mitos frecuentes de la retórica antivacunas y explicamos por qué está equivocada:

“No es para tanto”

Una idea errónea común es que las vacunas no son necesarias porque las enfermedades que previenen no son peligrosas u ocurren con muy poca frecuencia como para ser motivo de preocupación. Aunque se hayan reportado casos de sarampión en 19 estados, los escépticos acusan a funcionarios de salud pública y a los medios de comunicación de sembrar temor sobre la enfermedad sin fundamento.

Por ejemplo, una nota publicada en el sitio web del National Vaccine Information Center, una fuente habitual de desinformación sobre las vacunas, sostuvo que la preocupación creciente por el sarampión “es una exageración al estilo de ‘el cielo se cae'”. El artículo decía que contraer el sarampión, las paperas, la varicela y la gripe (también llamada influenza) era “políticamente incorrecto”.

Según los CDC, el sarampión resulta fatal en aproximadamente 2 de cada 1,000 niños infectados. Si este nivel de riesgo suena aceptable, vale la pena señalar que un número mucho mayor de niños con sarampión requieren hospitalización por neumonía y otras complicaciones serias.

Por cada 10 casos de sarampión, un niño con la enfermedad desarrolla una infección de oído que puede causar la pérdida auditiva permanente. Otro efecto extraño del virus es que puede destruir la inmunidad de una persona, y así afectar su capacidad para recuperarse de la gripe y otras afecciones comunes.

Las vacunas contra el sarampión han evitado la muerte de alrededor de 94 millones de personas, principalmente niños, en los últimos 50 años, según un análisis de abril de la Organización Mundial de la Salud (OMS). Junto con las vacunas contra la polio y otras enfermedades, se estima que las vacunas han salvado 154 millones de vidas en todo el mundo.

Algunos escépticos de las vacunas sostienen que las enfermedades que previenen ya no son una amenaza porque se han vuelto relativamente poco frecuentes en el país. (Lo cual es cierto, gracias a la vacunación). Es el razonamiento que invocó el cirujano general de Florida, Joseph Ladapo, durante un brote de sarampión en febrero, cuando dijo a los padres que sus hijos no vacunados podían seguir yendo a la escuela. “Hay mucha inmunidad”, dijo Ladapo.

A medida que esta actitud relajada hacia las vacunas convence a los padres de no dárselas a sus hijos, la inmunidad colectiva disminuye y los brotes serán cada vez más grandes y se propagarán más rápido.

En 2019, un brote de rápido crecimiento afectó a una comunidad con tasas de vacunación insuficientes en Samoa y mató a 83 personas en cuatro meses. Las tasas persistentemente bajas de vacunación contra el sarampión en la República Democrática del Congo mataron a más de 5,600 personas a causa de la enfermedad en brotes masivos el año pasado.

“Nunca se sabe”

Desde los orígenes de las vacunas, siempre ha existido un grupo que ha desconfiado porque no son naturales, en comparación con las infecciones y plagas que abundan en la naturaleza. Los miedos y dudas sobre las vacunas han ido cambiando a lo largo de las décadas. En el 1800, por ejemplo, los escépticos pensaban que las vacunas contra la viruela hacían que a las personas les salieran cuernos y que se comportaran como bestias.

En tiempos más recientes, los escépticos han vinculado las vacunas con una variedad de afecciones, desde el trastorno por déficit de atención e hiperactividad hasta el autismo y las enfermedades del sistema inmunológico. Los estudios científicos no respaldan estas afirmaciones.

La realidad es que las vacunas están entre las intervenciones médicas más estudiadas. En el siglo pasado, las vacunas han pasado por estudios científicos y ensayos clínicos masivos tanto en las fases de desarrollo como después, durante su uso generalizado.

Más de 12,000 personas participaron en los ensayos clínicos de la última vacuna aprobada para prevenir el sarampión, las paperas y la rubéola. Al probar la vacuna en un gran número de personas, los investigadores pueden detectar riesgos poco comunes, lo cual es importante porque se administran a millones de personas sanas.

Para evaluar los riesgos a largo plazo, los científicos analizan grandes cantidades de datos para identificar señales de daño. Por ejemplo, un grupo danés analizó una base de datos de más de 657,000 niños y encontró que aquellos que fueron vacunados contra el sarampión cuando eran bebés no tenían más probabilidades de ser diagnosticados con autismo que aquellos que no fueron vacunados.

En otro estudio, los investigadores analizaron registros de 805,000 niños nacidos entre 1990 y 2001 y no encontraron ninguna prueba de que las vacunaciones múltiples pudieran afectar el sistema inmune de los niños.

Pero las personas que promueven la desinformación sobre las vacunas, como el candidato a la presidencia Robert F. Kennedy Jr., descartan los estudios masivos respaldados por la ciencia.

Por ejemplo, Kennedy sostiene que los ensayos clínicos para las nuevas vacunas no son confiables porque no se compara a los niños vacunados con un grupo que recibe un placebo, como solución salina u otra sustancia sin efecto. En vez de utilizar un placebo, muchos ensayos modernos comparan las vacunas actualizadas con otras más antiguas. Esto se debe a que se considera no ético poner en peligro a los niños al darles una vacuna falsa cuando se conoce el efecto protector de la inmunización.

En un ensayo clínico de vacunas contra la polio realizado en la década de 1950, 16 niños que recibieron un placebo murieron de polio y 34 quedaron paralizados, dijo Paul Offit, director del Centro de Educación Sobre Vacunas del Hospital de Niños de Philadelphia y autor de un libro sobre la primera vacuna contra la polio.

“Demasiadas y demasiado pronto”

Varios de los libros sobre vacunas más vendidos en Amazon promueven la peligrosa idea de que los padres deberían omitir o retrasar la vacunación de sus hijos. “Puede ser que no todas las vacunas en el calendario de los CDC sean adecuadas para todos los niños en todo momento”, escribe Paul Thomas en su libro más vendido “The Vaccine-Friendly Plan”. Para respaldar su argumento, dice que los niños que han seguido “mi protocolo están entre los más sanos del mundo”.

Desde la publicación del libro, la licencia médica de Thomas fue suspendida temporalmente en Oregon y Washington.

La Junta Médica de Oregon documentó cómo Thomas convenció a los padres a omitir vacunas recomendadas por los CDC e “hizo llorar” a una madre que no estaba de acuerdo. Varios niños bajo su cuidado contrajeron tos ferina y rotavirus, ambas enfermedades que se previenen fácilmente con vacunas, escribió la junta.

Thomas le recetó suplementos de aceite de pescado y homeopatía a un niño que tenía una laceración profunda en el cuero cabelludo en lugar de darle una vacuna de emergencia contra el tétanos. El niño desarrolló un cuadro de tétanos grave y estuvo en el hospital por casi dos meses, donde tuvo que someterse a una intubación, una traqueotomía y una sonda de alimentación para sobrevivir.

El calendario de vacunación recomendado por los CDC se diseñó para proteger a los niños en los momentos más vulnerables de su vida y minimizar los efectos secundarios. Por ejemplo, la vacuna combinada contra el sarampión, las paperas y la rubéola no se administra durante el primer año de vida del bebé porque los anticuerpos que transmite temporalmente la madre pueden interferir con la respuesta inmunitaria. Y como algunos bebés no generan una respuesta inmunitaria fuerte con esa primera dosis, los CDC recomiendan una segunda dosis alrededor del momento en que los niños comiencen el jardín de infantes, ya que el sarampión y otros virus se propagan rápidamente en contextos grupales.

No se recomienda retrasar mucho más las dosis de esta vacuna ya que los datos sugieren que los niños vacunados a los 10 años o más tienen más probabilidades de desarrollar reacciones adversas, como convulsiones o fatiga.

Alrededor de una docena de otras vacunas siguen su propio esquema cronológico, con superposiciones para obtener la mejor respuesta. Los estudios han demostrado que la vacuna contra el sarampión, las paperas y la rubéola se puede administrar de forma segura y eficaz combinada con otras vacunas.

“Ellos no quieren que lo sepas”

En la introducción del nuevo libro de Ladapo sobre cómo superar el miedo en la salud pública, Kennedy compara al cirujano general de Florida con Galileo. Así como la Inquisición católica condenó al famoso astrónomo por promover teorías sobre el universo, sugiere Kennedy, las instituciones científicas reprimen a los disidentes de las vacunas por razones nefastas.

“La persecución de científicos y médicos que se atreven a cuestionar las doctrinas contemporáneas no es nada nuevo”, escribe Kennedy. Su compañera de fórmula, la abogada Nicole Shanahan, ha hecho campaña con la idea de que las conversaciones sobre los peligros de las vacunas se están censurando y que las corporaciones influyen sobre los CDC y otras agencias federales para ocultar datos.

En el podcast más escuchado en Estados Unidos, “The Joe Rogan Experience”, a menudo figuran invitados que desconfían del consenso científico. El año pasado, en el programa, Kennedy repitió el mito muchas veces desmentido de que las vacunas causan autismo.

Lejos de ignorar ese miedo, los epidemiólogos lo han tomado en serio. Han realizado más de una docena de estudios en busca de un vínculo entre las vacunas y el autismo, y no han encontrado ninguno. “Hemos refutado de manera concluyente la teoría de que las vacunas están relacionadas con el autismo”, afirmó Gideon Meyerowitz-Katz, epidemiólogo de la Universidad de Wollongong en Australia. “Es por esto que el sistema de salud pública tiende a cerrar esas conversaciones rápidamente”.

Las agencias federales son transparentes con respecto a las reacciones que pueden causar las vacunas, incluyendo convulsiones y dolor en el brazo. Y el gobierno tiene un programa para compensar a las personas si se determina científicamente que sus lesiones son el resultado de las vacunas. Alrededor de 1 a 3.5 de cada millón de dosis de la vacuna contra el sarampión, las paperas y la rubéola pueden provocar una reacción alérgica potencialmente mortal. Se estima que el riesgo de muerte a causa de un rayo durante toda la vida de una persona es hasta cuatro veces mayor.

“Lo más convincente que puedo decir es que mi hija tiene todas sus vacunas y que todos los pediatras y profesionales de salud pública que conozco han vacunado a sus hijos”, dijo Meyerowitz-Katz. “Nadie haría eso si pensara que existen riesgos graves”.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

USE OUR CONTENT

This story can be republished for free (details).

10 months 3 weeks ago

Health Industry, Noticias En Español, Public Health, States, Children's Health, Misinformation, Oregon, vaccines, Washington

Health Archives - Barbados Today

Ministry of Health clears air on social media reports about death of 8-month-old child

The Ministry of Health and Wellness wishes to address recent extremely serious misleading allegations which have been placed in the public domain, following the unfortunate and tragic death of an eight-month-old child.

On Thursday May 23, 2024 an eight-month-old child was referred to the Accident and Emergency Department (AED) of the Queen Elizabeth Hospital by a private medical practitioner. The child arrived at the AED in an unconscious state and died following failed resuscitation efforts.

It is known that in keeping with common practice for children of such age, the child had been immunised. The immunisations were administered at the St Philip Polyclinic including the two, four- and six-month vaccines, with the last dose being administered on April 2, 2024.

The MHW, however, wishes to clearly state that the child had not received the MMR vaccines as being misleadingly stated in the public domain. The policy of the MHW is that minimum age at which this vaccine is administered to children is one year of age.

In keeping with the Laws of Barbados, in cases of sudden and unnatural death, an autopsy will be conducted to determine the cause of this unfortunate death. The MHW takes this opportunity to extend its condolences to the family of the deceased child.

Vaccines have been issued by the expanded programme of immunisation in Barbados since the late 1970s. The vaccines used locally have been demonstrated to be effective at reducing the risk of disease. The Ministry of Health and Wellness reminds parents to keep their children’s vaccinations up-to-date according to the recommended schedule to the risk of vaccine-preventable diseases.

The Ministry further wants to clarify the incorrect information on COVID deaths in the public domain. These numbers stand at 648 with no deaths in the last reporting period of April 13th and May 10th. The COVID19 vaccine was made available to the public by Ministry of Health and Wellness during the pandemic as part of its commitment to use evidence-based measures to reduce the risk of severe illness and death.

The MHW urges members of the public to desist from spreading alarm amongst the population through the practice of maliciously circulating misinformation.

(Statement made by Dr Ingrid Cumberbatch, Senior Medical Officer of Health (South), Ministry of Health and Wellness on 26th May 2024.)

The post Ministry of Health clears air on social media reports about death of 8-month-old child appeared first on Barbados Today.

10 months 3 weeks ago

Death, Health, Local News

Health Archives - Barbados Today

Organisers: Prostate Cancer Run Walk a success

The Barbados Cancer Society is hailing Sunday’s Prostate Cancer Run Walk as a success.  Now in its second year, the event has seen a significant increase in participation and public engagement.

Michelle Straughn, walk manager for the event, speaking to the media after the starter fired the pistol to get walkers, runners, rollerbladers, skaters and children on scooters, underway, expressed her enthusiasm about the growing numbers and the importance of raising awareness for prostate cancer.

“This is now our second walk for the Prostate Cancer Walk. We started last year, it was our first. And we’ve certainly done a lot better this year in terms of numbers,” Straughn said. 

“We were expecting maybe about, I would say, 2,000 persons. And I believe that we would have gotten that. And we’re all excited because this means that awareness is spreading.”

Rollerbladers also took part in this year’s event.

She noted the initiative, aimed at bringing awareness to prostate cancer, served a crucial role as there was a critical need for early detection, not only for cancer but cancer of the prostate.

“It’s so important. The early detection of prostate cancer, as you know, is all about the males. And we have to protect them. So we’re very, very happy to see the response. And we know that next year will be better, because we have a bigger and better plan for next year. Maybe a lot more activities on the day. Listen out for it.”

There were some changes made this time around to the route, to accommodate different participants’ preferences. Whereas last year there was one route, Straughn explained some members of the public called for there to be a run in addition to the walk and this time around, the run was added along a separate route. (RG)

The post Organisers: Prostate Cancer Run Walk a success appeared first on Barbados Today.

10 months 3 weeks ago

Health, Local News

Health Archives - Barbados Today

PM Mottley presented with WHO award for exceptional leadership in health

Director-General of the World Health Organization (WHO) Tedros Adhanom Ghebreyesus on Sunday presented Prime Minister Mia Mottley with the Director-General’s Award for Global Health.

Mottley is one of three people being awarded this year.

Director-General of the World Health Organization (WHO) Tedros Adhanom Ghebreyesus on Sunday presented Prime Minister Mia Mottley with the Director-General’s Award for Global Health.

Mottley is one of three people being awarded this year.

The awards are usually presented during the WHO’s most important meeting of the year — the World Health Assembly, which is being held on Monday. However, Mottley was presented with the award at the WHO headquarters in Geneva, Switzerland, on Sunday to allow her to travel to Antigua and Barbuda for the United Nations fourth International Conference on Small Island Developing States (SIDS4), which begins on Monday.

Back in 2019, the WHO Director-General gave Global Health Leaders Awards to a number of individuals who have shown outstanding commitment to public health goals. The awards are now presented on an annual basis to selected individuals or groups of individuals who have demonstrated exceptional leadership to achieve tangible health impacts.

In her acceptance speech, Mottley thanked the WHO Director-General for being there and for steadfastly supporting small countries.

“[The] COVID pandemic for us was the wild wild west in every sense of the word. When we could access goods, we learned that export restrictions would be put on them. When we could access vaccines, export restrictions were also put on them. When we could pay, we couldn’t get orders because our orders were simply too small to be taken, whether for equipment or medicines,” Mottley said.

Both the WHO and the Pan American Health Organization stood up for the region, Mottley said, while also paying tribute to PAHO’s Director Emeritus Dr Carissa F Etienne who died last year.

“You were the two people who were directly accessible at midnight … and that speaks volumes to the difference you made in saving lives — I dare say hundreds of thousands, if not millions of lives across the Small Island Developing States,” Mottley said.

“I thank you on behalf of my country for the honour which you are conferring on me. I take it not as my own, I take it as an honour to Barbados.”

Mottely also saluted the island’s Chief Medical Officer, Dr Kenneth George, “who was on the front-lines, but I also want to salute my Ministers of Health, Lt Col Jeffrey Bostick and Senior Minister Jerome Walcot, who effectively carried and continue to carry the day-to-day battle in this critical area of health.”

The post PM Mottley presented with WHO award for exceptional leadership in health appeared first on Barbados Today.

10 months 3 weeks ago

Health, Local News

Health – Demerara Waves Online News- Guyana

Guyana’s life expectancy increasing; maternal, child mortality falling – President Ali

Guyanese are living longer and fewer mothers and children are dying, President Irfaan Ali announced Saturday night at a flag-raising ceremony held in Linden to usher in Guyana’s 58th Independence anniversary. He said that from 2020 to now, the country’s life expectancy has increased by two years overall to 70 in males, and 74 for ...

Guyanese are living longer and fewer mothers and children are dying, President Irfaan Ali announced Saturday night at a flag-raising ceremony held in Linden to usher in Guyana’s 58th Independence anniversary. He said that from 2020 to now, the country’s life expectancy has increased by two years overall to 70 in males, and 74 for ...

10 months 3 weeks ago

Health, News, Politics, child mortality, Healthcare, life expectancy, President Irfaan Ali

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

255 JR Post At RML Hospital Delhi: Check Out All Details Here

New Delhi: The Atal Bihari Vajpayee Institute of Medical Sciences and Dr Ram Manohar Lohia Hospital (ABVIMS & RML Hospital Delhi), has announced the vacancies for the post of Junior Resident (Non-Academic) on an regular basis in this medical institute. 

Dr Ram Manohar Lohia Hospital, formerly known as Willingdon Hospital, was established by the British for its staff and had only 54 beds. After independence, its control was shifted to New Delhi Municipal Committee. In 1954, its control was again transferred to the Central Government of Independent India.

RML Hospital Vacancy Details:Total no of vacancies: 255The last date for Submission of the Application is the 5th June 2024 till 3:00 p.m.For more details about Qualifications, Age, Pay Allowance, and much more, click on the given link:https://medicaljob.in/jobs.php?post_type=&job_tags=RML+Hospital&location=&job_sector=all

Eligible Candidates (How to Apply)?

1. Application should be submitted in Central Diary & Dispatch Section, Near Gate No. 3, ABVIMS & Dr. Ram Manohar Lohia Hospital, New Delhi-110001, latest by 05.06.2024 till 03:00 PM. The application send by post must be having written prominently on the top of the envelop "Application for the post of Junior Resident (Non-Academic). It is also informed that Hospital will not be responsible for any postal delay.

2. Prescribed Application form duly filled & signed (Annexure-l) should be accompanied with self altested copies of final year mark sheet of M.B.B.S pass certificale, DMC registration certificate, Internship completion certificate, Category clrtificate, 1Oth class pu..irg certificate and copy of Aadhar Card, pAN Card

3. Counseling will be done on the basis of merit in written examination for the allotment of seats in various departments.

4. The List of eligible applicants for the written examination will be uploaded on Hospital Website (www.rmlh.nic.in) only. After scrutiny the list of rejected applications will also be displayed on hospital website.

5. If it is found, that the applicant has suppressed any information or given wrong information his/her Junior Residency (Non - Academic) will be terminated forthwith without assigning any reason.

Note: It is informed that Dr. RML Hospital will not made individual communication to any candidate. All updates regarding list of eligible candidates, Admit Card, Result' Counseling, Offer Letter etc will be uploaded on Dr. RML Hospital official Website (www.rmlh.nic.in) only. The applicants are advised to visit the website regularly for any updates.

Also Read:204 JR Post In Various Departments At VMMC, Safdarjung Hospital: Apply Now

10 months 4 weeks ago

Jobs,State News,News,Health news,Delhi,Medical Jobs,Hospital & Diagnostics,Doctor News,Latest Health News,Recent Health News

Health Archives - Barbados Today

Minnie, 100, still does it all

The saying that age is just a number could easily be applied to 100-year-old Veronique Minnie McCollin.

Unlike many others in her age group, the island’s latest centenarian is independent. She takes her own baths, cooks her own meals and on top of that can boast of good health as she has no illnesses.

The saying that age is just a number could easily be applied to 100-year-old Veronique Minnie McCollin.

Unlike many others in her age group, the island’s latest centenarian is independent. She takes her own baths, cooks her own meals and on top of that can boast of good health as she has no illnesses.

At birthday celebrations at her house in Jackson Land, Silver Hill, Christ Church on Friday, Minnie, as she is affectionately called, told journalists that she was overjoyed to reach this milestone, even though she did not think she would. She said she loves cooking, especially making soup and makes sure to “put in everything”. She also likes to eat rice with vegetables and green bananas with salt fish.

Regarding her daily routine, she likes to be outdoors soaking up the fresh air. She said after taking her bath and drinking tea she would go outside and pray. Afterwards, she would watch people pass along the roadside. 

Minnie added that she came to Barbados after landing a job opportunity to take care of someone’s child. Her children said she left Dominica at age 18. 

She became known from then onward as a domestic worker of excellence and was showered with tributes during the celebrations.

Matriarch of the Jordan family, Marsha, said Minnie took care of her children and household needs for 35 years.

She described the birthday girl as a wonderful woman, who had a kind, calm and pleasant personality. She said she was also grateful for the nurture she gave her children and values she instilled in them. 

Minnie, who at one point lived in The Pine, St Michael, did small domestic chores after her time at the Jordans. Her children said her last official year of work was 2007.

President Dame Sandra Mason also paid Minnie a special visit and had a lively chat with the centenarian. 

sheriabrathwaite@barbadostoday.bb

The post Minnie, 100, still does it all appeared first on Barbados Today.

10 months 4 weeks ago

Health, Living Well, Local News

Health Archives - Barbados Today

Mosquito fair attracts pest killers

Mosquitoes – small bite, big threat.

This was the warning from Senior Environmental Officer responsible for vector control Dale Holligan as she joined her colleagues and partners of the Ministry of Health for a National Mosquito Fair. The event highlighted the integrated measures that the government uses to control mosquitoes, and encouraged the public to become more involved in mosquito prevention.

“Mosquitoes are more than just a bother; they are among the deadliest creatures out there,”  she warned, pointing to the recent dengue outbreak in Barbados earlier this year, as evidence of the threat they pose.

“We wanted to bring more public awareness to the mosquito population, their breeding habits, life cycle, habitats, and the surveillance and resistance testing conducted by the Ministry of Health,” Holligan told Barbados TODAY.

The event saw participation from Rentokil, Armstrong Agencies, and Massy, demonstrating a collaborative approach to mosquito control.

“It was not hard to get them on board,” Holligan said. “These organisations already work with vector control. It was best to have them here to show the public that it’s not only the government involved; there are other entities and products available for mosquito control.

She detailed practical steps residents can take to reduce mosquito breeding sites, especially with the rainy season approaching. “The first thing people need to do is check around their homes for containers that can collect water. If you need them, put them in areas where mosquitoes can’t reach them. If you don’t need them, discard them,” she advised. “Mosquitoes lay eggs in containers waiting for water. When it rains, these eggs develop into larvae. So, protecting or discarding containers is crucial.”

Holligan also urged residents to inspect their roof gutters, animal water containers, and any natural or man-made depressions where water might collect. “We need to be vigilant about our surroundings and ensure there are no areas where water can settle and provide breeding grounds for mosquitoes.”

Addressing the broader public health implications, Holligan noted that the Aedes aegypti mosquito, which spreads dengue, also carries other diseases like chikungunya, Zika, and yellow fever. “We don’t see yellow fever or malaria here because those diseases are carried by different mosquitoes. However, the threat remains significant.”

Despite ongoing efforts, the senior environmental officer acknowledged the challenges in getting the public to take preventive measures seriously. “People tend to be more responsive after experiencing one of these diseases. Until then, mosquitoes are often just seen as nuisances,” she said.

The event is part of a larger outreach programme aimed at increasing public participation in vector control. “You can expect to see more events like this, possibly in combination with rodent control initiatives,” Holligan confirmed.

 

The post Mosquito fair attracts pest killers appeared first on Barbados Today.

10 months 4 weeks ago

Environment, Health, Local News

PAHO/WHO | Pan American Health Organization

OPS insta a fortalecer medidas preventivas contra el dengue en Centroamérica, México y el Caribe

PAHO urges countries to strengthen dengue prevention in Central America, Mexico and the Caribbean

Cristina Mitchell

24 May 2024

PAHO urges countries to strengthen dengue prevention in Central America, Mexico and the Caribbean

Cristina Mitchell

24 May 2024

10 months 4 weeks ago

Health Archives - Barbados Today

‘Run up’: Prostate cancer screening on the rise

The Barbados Cancer Society has credited rising numbers of men getting screened for prostate cancer to heightened awareness and the introduction of simpler, less invasive testing.

This positive trend comes as the organisation prepares for its second annual Cemix Prostate Cancer Run/Walk, set for Sunday at 3 p.m. at the Garrison Savannah. The event aims to raise further awareness and support for early detection of prostate cancer.

During a site visit at the Garrison Savannah, where the event will kick off, Michelle Straughn, walk manager for the Barbados Cancer Society, said the simplified testing process has had a significant impact on numbers.

“Early detection is important in any disease and before it used to be an invasive test, but it’s changed to a blood test. So if the PSA [prostate-specific antigen] levels are raised, then you get further tests,” she said.

Straughn also noted the availability of a DNA test for genetic predisposition to prostate cancer at a reduced price, making early detection more accessible.

“If there were any males in your family that would have had prostate cancer, then obviously you would have a greater level of being susceptible to the disease,” she said. “So there’s also a DNA test that can be done to show if it’s in your family line and that test is at a reduced price of $200,” she said, noting a significant reduction from the usual cost of around $1 000.

The event manager stressed the importance of community support in conducting the necessary research on prostate cancer and further offsetting associated costs for men across the island.

Straughn outlined the routes for the walk and run which will both start and end at the Garrison, with the run beginning at 3:45 p.m. and the walk at 4 p.m.

She added that partners, the Scottish District Grand Lodge of Barbados, were instrumental in putting the routes together.

Glyne Grannum, a member of the lodge, said: “This is a very important event for Barbadian men and we were very privileged … when we were able to find a willing partner to raise the profile of the disease and its impact on Barbadian men and at the same time, to be able to, from that awareness, get greater sponsorship for the issue.”

Grannum also revealed what he described as a significant increase in registration by lodge members.

“The registration for this year from the Scottish District Grand Lodge is indeed a greater number than last year and not only testimony to the seriousness with which the lodge treats this project but also wider understanding within Barbados,” he said.

The organisers have called on the community to join the event, highlighting the collective effort needed to continue improving health outcomes for Barbadian men.

The post ‘Run up’: Prostate cancer screening on the rise appeared first on Barbados Today.

10 months 4 weeks ago

Health, Local News

Health Archives - Barbados Today

Health charity’s hands-on approach

A new charity is taking a proactive stance on improving health and wellness within vulnerable communities, going beyond traditional methods to provide practical solutions directly where they are needed most.

The HNI Foundation, the non-profit arm of the Healthier Nation Initiative co-founded by Sheldon Jones, has been working to uplift lower socio-economic areas across the island and the Caribbean. Its mission is to deliver accessible and sustainable healthcare services to those struggling with economic disadvantages.

“The foundation’s mandate is to provide practical, accessible, and sustainable health and wellness solutions to vulnerable populations in lower socio-economic communities in Barbados and the wider region,” Jones explained. Unlike many organisations that solely offer education, HNI takes a more hands-on tack. “While education is essential, we found that economic factors significantly impact a person’s ability to act on that education.”

To bridge this gap, the foundation brings free exercise programmes, medical testing through partnerships with Ross University, and collaborative efforts offering health services directly to communities at little to no cost. “We’re bringing solutions into the community, ensuring that even those in high-risk categories have access to the resources they need to manage their health better,” Jones added.

The foundation has identified key demographics in significant need of assistance, including single mothers, the elderly and disabled persons – groups often at higher risk for diseases. By conducting wellness checks and providing fitness programmes and health packages, HNI aims to manage and mitigate these risks through close cooperation with community leaders.

At an outreach event in Hillaby, St Andrew, residents began arriving from 7.30 a.m., for the 8 a.m. start. Jones praised the collaborative approach: “Our team deserves full credit. We aimed to create a more community-focused approach, less corporate, and more personal.”

He highlighted the vital roles played by community liaison officers Rosemary Clarke and Gillian Marshall in personally engaging with local leaders, as well as project officer Carl Griffith’s organisational efforts. “Our approach, centred on personal engagement, makes a significant difference. It transforms HNI from a nameless, faceless entity into a group of people genuinely interested in the community’s well-being.”

The partnership with Ross University was also hailed as a “godsend”, with representatives ensuring free, comprehensive medical checks through the involvement of students. Jones emphasised the aim of empowering people to take charge of their health: “It’s not that difficult to be healthy. It requires intentionality, just like any other goal. Health is based on movement, a balanced diet, and regular check-ups.”

While the outreach saw an impressive turnout, with up to 30 people at a time, quality remained the focus. “It’s about providing thorough, meaningful checks to a targeted group,” said Jones. “The feedback has been overwhelmingly positive.”

Looking ahead, HNI has ambitious plans for regional expansion to territories like Antigua and Grenada this year, aided by a partnership with financial services giant Sagicor. Jones emphasised the importance of sustainability and follow-up assessments to gauge the effectiveness of their interventions over time.

He also highlighted the need to combat increasingly sedentary modern lifestyles: “Movement is crucial, yet often overlooked. Many jobs today are sedentary, contributing to health risks. As a personal trainer, I emphasise that exercise doesn’t mean going to a gym—it’s about finding enjoyable activities to stay active.”

For those inspired by HNI’s work, Jones offered this message: “Improving your quality of life is simpler than it seems. Small changes in diet and regular movement can make a big difference. Find activities you enjoy staying active and make balanced dietary choices. Even minor adjustments can significantly enhance your health and well-being.”

 

The post Health charity’s hands-on approach appeared first on Barbados Today.

10 months 4 weeks ago

Charity, Health, Local News

PAHO/WHO | Pan American Health Organization

COVID-19 eliminated a decade of progress in global level of life expectancy

COVID-19 eliminated a decade of progress in global level of life expectancy

Cristina Mitchell

24 May 2024

COVID-19 eliminated a decade of progress in global level of life expectancy

Cristina Mitchell

24 May 2024

10 months 4 weeks ago

Medical News, Health News Latest, Medical News Today - Medical Dialogues |

Once-weekly insulin efsitora alfa as effective as daily basal insulin in type 2 diabetes, find trials

Researchers have found in phase 3 QWINT-2 and QWINT-4 trials that Once-weekly insulin efsitora alfa was as effective as daily basal insulin in adults with type 2 diabetes.

In the treat-to-target clinical trials, efsitora showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally.

Researchers have found in phase 3 QWINT-2 and QWINT-4 trials that Once-weekly insulin efsitora alfa was as effective as daily basal insulin in adults with type 2 diabetes.

In the treat-to-target clinical trials, efsitora showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally.

"The results of QWINT-2 and QWINT-4 are a significant milestone for the diabetes community and demonstrate that efsitora as a weekly insulin provides blood sugar control equivalent to daily basal insulins," said Jeff Emmick, MD, Ph.D., senior vice president, product development, Lilly. "With efsitora, we have an opportunity to provide an innovative once-weekly solution that safely achieves and maintains A1C control, reduces treatment burden of traditional daily injections and potentially improves adherence for people with diabetes."

QWINT-2 evaluated the efficacy and safety of once-weekly efsitora compared to once-daily insulin degludec for 52 weeks. The trial randomized insulin-naïve adults with type 2 diabetes to receive efsitora once weekly or insulin degludec once daily and was also designed to assess efficacy in patients using and not using GLP-1 receptor agonists.

The trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin degludec at week 52. For the efficacy estimand, efsitora reduced A1C by 1.34% compared to 1.26% for insulin degludec resulting in an A1C of 6.87% and 6.95% respectively. In a key secondary endpoint, efsitora was non-inferior to insulin degludec in A1C change among participants using and not using GLP-1 receptor agonists. Further, participants taking efsitora spent 45 minutes more time in range and 37 minutes more in tight range without additional time in hypoglycemia (blood glucose <54 mg/dL) in comparison to insulin degludec.

QWINT-4 evaluated the efficacy and safety of efsitora compared to insulin glargine for 26 weeks in adults with type 2 diabetes who have previously been treated with basal insulin and at least two injections per day of mealtime insulin. The trial randomized participants to receive efsitora once weekly or insulin glargine once daily, both of which were administered with insulin lispro.

The trial met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin glargine at week 26. For the efficacy estimand, both efsitora and insulin glargine reduced A1C by 1.07% resulting in an A1C of 7.12% and 7.11%, respectively6,7.

In both QWINT-2 and QWINT-4, efsitora was safe and well-tolerated with estimated combined rates of severe or clinically significant (blood glucose <54 mg/dL) hypoglycemic events per patient-year of exposure of 0.58 with efsitora vs. 0.45 with insulin degludec (QWINT-2) and 6.6 with efsitora vs. 5.9 with insulin glargine (QWINT-4).

Detailed results from QWINT-2 will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024. Topline readouts from QWINT-1, QWINT-3 and QWINT-5 are anticipated later this year.

About the QWINT clinical trial program

The QWINT phase 3 global clinical development program for insulin efsitora alfa (efsitora) in diabetes began in 2022 and has enrolled more than 4,000 people living with type 1 or type 2 diabetes across five global registration studies.

QWINT-2 (NCT05362058) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin to insulin degludec for 52 weeks in insulin-naïve adults with type 2 diabetes. The trial randomized 928 participants across the U.S., Brazil, Canada, China, Czechia (Czech Republic), Germany, Greece, Japan, Korea, Mexico and Puerto Rico to receive efsitora once weekly or insulin degludec once daily administered subcutaneously. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 52 with efsitora compared to insulin degludec. The trial was also designed to assess efficacy and safety for patients using and not using GLP-1 receptor agonists.

QWINT-4 (NCT05462756) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a weekly basal insulin to insulin glargine for 26 weeks in adults with type 2 diabetes who have previously been treated with basal insulin and at least two injections per day of mealtime insulin. The trial randomized 730 participants across the U.S., Argentina, Germany, India, Italy, Mexico, Puerto Rico and Spain to receive efsitora once weekly or insulin glargine once daily, both of which were administered subcutaneously along with insulin lispro. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin glargine.

About insulin efsitora alfa

Insulin efsitora alfa (efsitora) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase 3 development for adults with type 1 and 2 diabetes.

11 months 9 hours ago

Diabetes and Endocrinology,Medicine,Diabetes and Endocrinology News,Medicine News,Top Medical News,Latest Medical News

Pages